FinTechFunding

Avecho Biotechnology: Completes pharmaceutical CBD capsule

Avecho Biotechnology (ASX:AVE) completes pharmaceutical CBD capsule

  • Avecho Biotechnology (AVE) has completed the composition and design of the dosage form of its cannabidiol soft-gel product
  • The appointed manufacturer of the cannabidiol (CBD) product, Catalent, completed the capsules intended for registration with the TGA
  • The CBD capsules will be used in Avecho’s upcoming clinical trial campaign, which includes phase one and a pivotal efficacy study
  • The finalised composition will contain 75 milligrams of CBD per soft-gel capsule
  • Production will start at a small scale to validate the manufacturing process and analytical methods
  • The company is up 13.3 per cent, trading at 1.7 cents

 

Previous article
Westar: Launches maiden drill campaign at Gidgee South
Next article
Tenstorrent: Raises Over $200M in Funding; Valued at $1 Billion
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

UK Banks Reject Opportunity to Lift £100 Contactless Limit

Major UK banks choose not to increase contactless payment thresholds.Highlights: UK banks will not raise the £100 contactless...
FinTech

Crypto.com Cuts 12% of Workforce Amid AI Shift

The company streamlines operations in response to evolving market dynamics.Highlights: Crypto.com reduces workforce by 12%Focus shifts to AI...
FinTech

Tide Strengthens Leadership with PPRO CTO Appointment

The fintech company welcomes a new chief technology officer to enhance its team.Highlights: Tide appoints ex-PPRO CTO to...
FinTech

Visa Overcomes Legacy Issues with Unified API for Intelligent Authorization

New API aims to streamline payment processes and enhance security features.Highlights: Visa launches a unified API to improve...